ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

Portfolio Tracker
Get an update on your stocks every day. See earnings revisions, new reports and Zacks Rank changes at a glance. Click here to learn more.

Quote:

Search for Ticker

Free Membership

Search:

OSIR: Osiris Therapeutics Inc - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

OSIRIS THERAPEUTICS INC (NASD)
OSIR	6.52	-0.02	(-0.31%)	Vol. 75,393	16:00 ET

OSIRIS THERAPEUTICS, INC. is a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas. Osiris currently markets and sells Osteocel for regenerating bone in orthopedic indications. Prochymal is being evaluated in Phase III clinical trials for three indications, including acute and steroid refractory Graft versus Host Disease and also Crohn's disease, and is the only stem cell therapeutic currently designated by FDA as both an Orphan Drug and Fast Track product. Osiris also has partnered with Genzyme Corporation to develop Prochymal as a medical countermeasure to nuclear terrorism and other radiological emergencies. Osiris is a fully integrated company, having developed capabilities in research, development, manufacturing, marketing and distribution of stem cell products.

General Information

OSIRIS THERAPTC

7015 Albert Einstein Drive Columbia, MD 21046-1707 Phone: 443-545-1800 Fax: 443-545-1701 Web: www.osiristx.com Email: None

Industry	MED-BIOMED/GENE
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	09/30/09
Next EPS Date	02/19/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	6.54
52 Week High	21.65
52 Week Low	5.35
Beta	-0.13
20 Day Moving Average	212,963.55
Target Price Consensus	5.9

% Price Change
4 Week	1.55
12 Week	-54.41
YTD	-65.71

% Price Change Relative to S&P 500
4 Week	0.45
12 Week	-57.02
YTD	-71.62

Share Information
Shares Outstanding (millions)	32.76
Market Capitalization (millions)	215.23
Short Ratio	7.02
Last Split Date	N/A

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	0.16
Current Year EPS Consensus Estimate	0.09
Estimated Long-Term EPS Growth Rate	-
Next EPS Report Date	02/19/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	2.25
30 Days Ago	1.75
60 Days Ago	1.75
90 Days Ago	1.75

Fundamental Ratios

P/E
Current FY Estimate:	75.09
Trailing 12 Months:	-
PEG Ratio	-

EPS Growth
vs. Previous Year	66.67%
vs. Previous Quarter	19.23%

Sales Growth
vs. Previous Year	963.72%
vs. Previous Quarter:	1.10%

Price Ratios
Price/Book	-
Price/Cash Flow	-
Price / Sales	5.39

ROE
09/30/09	-2,486.93
06/30/09	-25,755.17
03/31/09	-

ROA
09/30/09	-26.70
06/30/09	-43.41
03/31/09	-67.13

Current Ratio
09/30/09	1.85
06/30/09	2.08
03/31/09	2.35

Quick Ratio
09/30/09	1.85
06/30/09	2.08
03/31/09	2.35

Operating Margin
09/30/09	-88.12
06/30/09	-159.13
03/31/09	-259.62

Net Margin
09/30/09	-94.70
06/30/09	-167.00
03/31/09	-262.94

Pre-Tax Margin
09/30/09	-94.70
06/30/09	-167.00
03/31/09	-262.94

Book Value
09/30/09	-0.10
06/30/09	0.09
03/31/09	0.34

Inventory Turnover
09/30/09	-
06/30/09	-
03/31/09	-

Debt-to-Equity
09/30/09	0.00
06/30/09	0.00
03/31/09	0.00

Debt to Capital
09/30/09	-
06/30/09	0.00
03/31/09	0.00


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research